대한뉴팜

Daehan New Pharm Co., Ltd. (054670) has promoted the license-in of internal and external deworming products for companion animals through a strategic partnership with the Irish pharmaceutical company Chanelle Pharma Group, established in 2018. As a result, in January 2020, the company launched ‘Fipnil Spot-On,’ an animal pharmaceutical product containing the active ingredient ‘Fipronil.’

Fipronil is a phenylpyrazole compound that, when applied directly to companion animals, binds to GABA receptors in the nervous system of external parasites such as fleas and ticks. It acts as an antagonist to chloride ion channels, causing hyperpolarization that leads to parasite death.

When applied to the skin of the companion animal's shoulder blade area (between both shoulders), the product spreads over the body within 24 hours through the lipid-rich layer of the skin. It concentrates and is stored in sebaceous glands and hair follicles under the skin, maintaining its effect by being released through the skin and hair for more than a month.

Based on the advanced technology of Chanelle Pharma Group that maximizes the action mechanism of Fipronil, ‘Fipnil Spot-On’ has demonstrated superior product efficacy through bioequivalence tests and comparisons with original products tested not only in the EU but also in multiple countries worldwide.

According to the “Survey Report on Companion Animal Ownership and Public Awareness (2017)” by the Korea Pet Food Association, among 19.56 million households in Korea, 5.63 million (28.8%) own companion animals. The estimated number of companion dogs is about 6.6 million, and companion cats about 2.07 million. Companion animal ownership has increased roughly 57% over the past five years, and this trend is expected to continue due to factors such as nuclear family structure, an increase in single-person households, aging population, and higher income levels. Additionally, the rise in vector insects due to global warming and increased contact between companion animals and wildlife vectors pose ongoing challenges. Therefore, prevention through internal and external antiparasitic products for companion animals is essential to protect both animal and owner health. The domestic market for such products has grown to over 20 billion won.

The head of Daehan New Pharm's animal pharmaceuticals division stated, “By supplying the competitively positioned ‘Fipnil Spot-On’ developed through strategic cooperation with Chanelle Pharma Group’s technology, we expect to become a leading player in the steadily growing domestic internal and external deworming market for companion animals.”